Racotumomab (trade name Vaxira) is a non-small cell lung cancer (NSCLC) vaccine developed by researchers at the Center of Molecular Immunology, Cuba in collaboration with researchers from the Buenos Aires University, Argentina with promising results. It was granted certificate of approval by the State Center for Quality Control of Medicines of Cuba and by January,...
